布地奈德福莫特罗粉吸入剂与沙美特罗替卡松粉吸入剂治疗支气管哮喘的效果比较

Comparison of Effect of Budesonide and Formoterol Fumarate Powder for Inhalation and Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in treating Bronchial Asthma

目的:比较布地奈德福莫特罗粉吸入剂与沙美特罗替卡松粉吸入剂治疗支气管哮喘的效果。方法:选取2022年6月—2023年6月临清市人民医院收治的80例支气管哮喘患者作为研究对象,采用随机数字表法分为对照组与观察组,各40例。对照组给予沙美特罗替卡松粉吸入剂治疗,观察组给予布地奈德福莫特罗粉吸入剂治疗。比较两组治疗效果。结果:两组治疗总有效率比较,差异无统计学意义(P>0.05)。观察组咳嗽、喘息消失时间早于对照组,差异有统计学意义(P<0.001)。治疗1个月后,两组呼气峰值流速、第1秒用力呼气容积、用力肺活量高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗1个月后,两组日间症状评分低于治疗前,且观察组低于对照组,两组夜间憋醒次数少于治疗前,且观察组少于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:布地奈德福莫特罗粉吸入剂与沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床效果、用药安全性无明显差异,但布地奈德福莫特罗粉吸入剂可以更好地改善患者肺功能,促进症状消失,减轻日间症状,减少夜间憋醒次数。

Objective:To compare the effect of budesonide and formoterol fumarate powder for inhalation and salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of bronchial asthma.Methods:A total of 80 patients with bronchial asthma admitted to Linqing People's Hospital from June 2022 to June 2023 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 40 cases in each group.The control group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation,and the observation group was treated with budesonide and formoterol fumarate powder for inhalation.The treatment effects were compared between the two groups.Results:There was no significant difference in the total effective rate of treatment between the two groups(P>0.05).The disappearance of cough and gasping in the observation group was earlier than that in the control group,and the difference was statistically significant(P<0.001).After 1 month of treatment,the peak expiratory flow,forced expiratory volume in 1 second,and forced vital capacity in the two groups were higher than those before treatment,these indicators in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).After 1 month of treatment,the daytime symptom scores in the two groups were lower than those before treatment,the scores in the observation group were lower than those in the control group,and the number of nighttime awakenings in the two groups was less than that before treatment,the number in the observation group was less than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:There is no significant difference in the clinical efficacy and safety of budesonide and formoterol fumarate powder for inhalation and salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of bronchial asthma,but budesonide and formoterol fumarate powder for inhalation can better improve lung function,promote symptom disappearance,reduce daytime symptoms,and reduce the number of nighttime awakenings.